Table 3 Protein expression in uterine clear cell cancers (UCCC, N = 48), versus uterine endometrial (UEnd, N = 28) and ovarian clear cell (OvCC, N = 8) cases

ER positive

UCC

6

13%

UEnd

18

64%

1.2 E−05

OvCC

0

0%

0.65

PR positive

UCC

4

8%

UEnd

15

54%

4.8 E−05

OvCC

0

0%

0.90

P16 positive

UCC

18

38%

UEnd

14

50%

0.41

OvCC

4

50%

0.78

P53 mutant profile

UCC

11

23%

UEnd

6

21%

0.94

OvCC

1

13%

0.75

PTEN loss

UCC

28

58%

UEnd

18

64%

0.79

OvCC

4

50%

0.96

PDL1 positive

UCC

4

8%

UEnd

0

0%

0.30

OvCC

0

0%

0.92

MMRd

UCC

19

40%

UEnd

9

32%

0.69

OvCC

0

0%

0.07

MMRd2

UCC

10

21%

UEnd

6

21%

1

OvCC

0

0%

0.36

Mean (SD)

EZH2 expression^a

UCC

24.3% (39.2)

0.38, Kruskal–Wallis

UEnd

36.6% (41.7)

OvCC

17.5% (26.0)

γH2AX expression^a

UCC

18.3% (31.1)

0.54, Kruskal–Wallis

UEnd

24.7% (38.1)

OvCC

11.4% (29.8)